Introduction
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatological conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) is well established. They provide anti-inflammatory and analgesic effects and have the potential to improve musculoskeletal function in these common conditions. However, as long-term administration of NSAIDs is often necessary, the beneficial effect of these drugs must be carefully balanced against the possible harm that they may cause in several organ systems. The potential size of this problem can be seen when it is considered that 18.5 million NSAID prescriptions are written in England and Wales each year and many more are purchased over the counter. With the discovery and development of selective Cyclooxygenase-2 (COX-2) inhibitors, there was the promise of a preservation of effective anti-inflammatory properties while reducing the risk of serious gastrointestinal (GI) and renal pathology. With time though, a more complex picture has emerged regarding the effect of these selective inhibitors on hypertension, cardiovascular and renal risk. This risk profile is made more complex when preexisting, age-related conditions such as hypertension, ischaemic heart disease and congestive cardiac failure coexist. In addition, in the RA group, there is a significant and often under-recognised associated morbidity and premature mortality, much of which is attributable to cardiovascular disease. In fact, it now appears that RA should itself be considered an independent risk factor for atherosclerosis. It is thus clear that, in this group of patients, any additional cardiovascular risk must be kept to a minimum, and here we consider the potential effect of COX-2 inhibition on cardiovascular disease, focusing in particular on hypertension.
Since COX-2 was characterised in 1991, important differences between it and COX-1 have been established. Initially, it was identified that the principle eicosanoids (prostaglandin, thromboxane and leukotrienes), were generated de novo from phospholipids via the COX pathway. Cell damage activates the pathway leading to production of prostaglandin E 2 (PGE 2 ), a major mediator of the inflammatory response and protector of gastric mucosa; prostacyclin (PGI 2 ), a potent vasodilator and inhibitor of platelet aggravation; and thromboxane (TXA 2 ), the activity of which, in contrast to PGI 2 causes platelet aggregation and vasoconstriction. When the new 'inducible' form of COX was discovered, it was hoped that selective inhibition of COX-2 would provide a powerful anti-inflammatory effect while allowing the 'constitutive' COX-1 to continue producing eicosanoids that protect gastric mucosa and regulate renal function. However, with time it has become clear that although COX-2 is activated by pro-inflammatory mediators, it is also found in a 'constitutive' form within the kidney, small intestine, central nervous system and endothelium. The activities of both isoenzymes are illustrated in Figure 1 . Both COX-1 and -2, therefore, play important physiological roles within these tissues, with COX-2 activity upregulated in multiple sites under conditions of inflammation and stress. This is particularly important within the kidney where high levels of COX-2 are found in the macula densa and adjacent cortical thick ascending limb and in the medullary interstitial cells. 1 Changes in the activity of COX in these sites will effect blood pressure control.
COX-2 and hypertension
In the general population, recent studies have shown that there is no safe target blood pressure, with a linear relationship existing between blood pressure and cardiovascular and cerebrovascular disease. 2 A sustained increase of 3 mmHg systolic blood pressure could lead to a 10-20% increase in congestive cardiac failure and a 12% increase in angina. 3 This illustrates the importance of tight blood pressure control with effective monitoring and risk factor modification, which includes druginduced effects. The influence of NSAIDs on blood pressure is well documented with average increases in systolic blood pressure of between 3 and 5 mmHg. 4, 5 Although this adverse effect was initially thought to be less for the specific COX-2 inhibitors, molecular studies and clinical data suggest that this is not the case.
The hypertensive effects of NSAIDs arise as a result of the inhibition of prostaglandins, particularly PGE 2 and PGI 2 , in the kidney. 6 PGE 2 reduces sodium and water resorption in the collecting duct and thick ascending limb of the loop of Henle. This is both by a direct action and by an enhanced response to antidiuretic hormone. Inhibition of PGE 2 , therefore, increases tubular sodium and water reabsorption and can give rise to hypertension and oedema. The relative contribution of COX-1 and -2 on production of prostaglandins important in regulating fluid retention was not precisely known. However, it now appears that this effect is mostly COX-2 mediated, with clinical studies demonstrating similar levels of sodium retention in patients on nonspecific NSAIDs and those on COX-2-specific agents, with a frequency of clinical oedema between 2 and 5% for both groups. 7 It is not solely an effect of fluid retention that leads to a potential rise in BP. In the endothelium, production of the vasodilator PGI 2 is primarily via a COX-2-dependent pathway. 8 Figure 1 Role of the cyclooxygenase isoforms (COX-1 and COX-2) in the production of the constitutive and inducible eicosanoids (prostaglandins, thromboxane and leukotrienes). The primary function of each eicosanoid is shown.
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which is exclusively COX-1 mediated. The effect of prostaglandin inhibition is most marked in conditions of relative renal hypoperfusion. 9 Interference with COX activity has a more deleterious effect on renal blood flow and therefore glomerular filtration rate in those patients with impaired renal function and in the elderly. It is in these patient groups in whom NSAIDs and COX-2 inhibitors should be used with extreme caution.
Data from animal studies and clinical trials indicate that the adverse effects of COX-2 inhibitors on blood pressure occurs at a similar frequency to standard NSAIDs supporting the important role of COX-2 in vasomotor control. Hermann et al 10 created an experimental model of hypertension using salt-sensitive (DS) and salt-resistant (DR) Dahl rats. Blood pressure increased with sodium diet in the DS group but was more pronounced following 21 days of diclofenac (6 mg/kg/day) and the highly selective COX-2 inhibitor, rofecoxib (2 mg/kg/day), but surprisingly was slightly decreased by celecoxib (25 mg/kg/day) compared with DS-placebo. Thus, the effect of specific COX-2 inhibition was equivalent to that of a standard NSAID, but in this model, celecoxib, another selective COX-2 inhibitor, may have an additional mode of action independent to its COX inhibition.
Information from clinical trials is limited to a few randomised controlled trials (RCT) reporting the incidence of hypertension as a primary end point, and two large gastrointestinal outcome trials reporting hypertension and cardiovascular risk as secondary end points. Where there was no prior history of hypertension, one small double blinded RCT of 67 subjects compared four treatment groups: rofecoxib 25 mg o.d., celecoxib 200 mg b.d., naproxen 500 mg b.d. or placebo for 14 days.
11 No significant differences were seen in blood pressure or sodium excretion between the three active treatment groups, but no comparison was made with the placebo group. This was a short-term study, not representative of chronic anti-inflammatory use and the additional comorbidity that is often seen in RA and OA.
When patients with concurrent hypertension who were already on antihypertensive therapy were examined in a 6-week study of 810 OA patients, aged 65 years or more, it was found that the incidence of clinically important hypertension (defined as changes of more than 20 mmHg or an absolute systolic BP of 4140 mmHg) was 17% in the rofecoxib (25 mg/day) group and 11% in the celecoxib (200 mg/day) group. 12 In the long term, this hypertensive effect would lead to a significant increase in cardiovascular risk. In addition, there was a high incidence of significant oedema (9.5% in the rofecoxib group and 4.9% in the celecoxib group). These data on the incidence of hypertension are slightly higher than those recorded in the large gastrointestinal outcome studies where hypertension was an investigator reported outcome and not a defined primary end point. 13, 14 In the VIGOR study, use of Vioxx 50 mg (twice the standard dose used in RA) had a 9.7% investigator reported incidence of hypertension as compared to 5.5% reported with naproxen. 13 In the CLASS trial, celebrex 400 mg b.d. had a 1.6% hypertensive event reported compared to 2.1% in comparator NSAIDs (ibuprofen and diclofenac).
14 As hypertension was a spontaneously reported outcome and not defined by a threshold value in either of these trials, there are no details on the level of hypertension recorded or whether therapy was initiated.
COX-2 and endothelial dysfunction
No discussion on the effects of COX-2 inhibitors on hypertension would be complete without consideration of how these drugs may alter cardiovascular risk in other ways. This is of particular relevance to their use in RA where there is a well established enhanced risk of ischaemic events and in OA where the treated population is typically elderly. Several small studies have looked at the effect of COX-2 inhibition on endothelial cell dysfunction (ECD), a well-established surrogate for the development of IHD. As we have seen, the endothelium plays an important role in regulating vascular haemostasis with alterations in peripheral vascular resistance contributing to hypertension. Selective inhibition of COX-2, the major source of endothelium derived prostacyclin, may have an adverse effect on endothelial cell function, but conflicting data have emerged.
It is likely that endothelial COX-2 is expressed in response to vascular smooth muscle injury and by laminar shear stress. In addition, COX-2 expression has been found to be upregulated in atheromatous plaques, leading to speculation that COX-2 inhibition may actually lead to a reduction in vascular inflammation. 15 This may well be as a result of less vasoconstrictor COXase products, for example reactive oxidase species (ROS). 10 One animal study showed a reduction in atherosclerosis after 6 weeks of rofecoxib. 16 In support of this beneficial effect on the endothelium, a small double-blinded placebocontrol trial looked at the effect of celecoxib 200 mg b.d. on the endothelium of patients with severe coronary artery disease. The study found that celecoxib improved endothelial function, reduced levels of highly selective CRP and reduced markers of oxidative stress, oxidised LDL, when compared with a placebo group. 17 Conversely, PGI 2 -deficient mice, mimicking the effect of COX-2 inhibition, appear to have an increased response to injury leading to vascular proliferation and platelet activation. 18 Several other studies examining ECD have shown an adverse effect on EC function; however, no common trend has appeared. Within the available studies, many different methodologies to assess ECD have been employed, varied patient groups studied and variable doses and duration of therapy used with a variety of COX-2-specific inhibitors. These experimental factors will be important given that there are alterations in expression of COX-2 in the presence of ischaemia, there is the possibility of differing responses of coronary to forearm vessels and there is a difference in effect of short against long-term inhibition of endothelial prostacyclin production on blood vessel function. Further studies will be needed to clarify the acute and chronic effects of specific COX-2 inhibition on ECD and to establish whether these are adverse effects or not. This may be of particularly importance in patients with RA where drug-induced acute perturbation of EC function may exacerbate pre-existing atherosclerosis, while chronic effects may enhance the overall cardiovascular risk.
COX-2 and cardiovascular risk
Whether the effects of COX-2 inhibition on BP and the possible influence on EC function contribute to an actual increased risk in ischaemic cardiovascular events is unclear. However, other evidence from large-scale clinical trials raises the possibility of altered rates of actual ischaemic events in RA patients treated with specific COX-2 inhibitors. 13 Other mechanisms relating to thrombotic risk now need to be considered. As there is an absence of COX-2 expression on mature human platelets, COX-2 inhibitors therefore, do not inhibit prothrombotic TXA 2 . There is thus a theoretical risk from COX-2-sensitive inhibition of vasodilatory PGI 2 allowing the effects of unopposed TXA 2 action on vascular haemostasis. It is conceivable that this imbalance between the anti-and prothrombotic eicosanoids will lead to an increase in thrombotic, and therefore cardiovascular risk.
Our knowledge of actual ischaemic cardiovascular side effects of COX-2 inhibitors is in the context of two large GI outcome studies and meta-analysis of phase II-V product data. In the VIGOR study, 8076 patients with RA were randomised to rofecoxib 50 mg/day or naproxen 500 mg/b.d. and the primary end point was defined as upper GI events. 13 There was a significant reduction in GI events per 100 patient years (4.5% in the naproxen group and 2.1% in the rofecoxib group). However, the incidence of myocardial infarction (MI) was five times higher in the rofecoxib group than the naproxen group (0.4%, cf. 0.1%). There are some difficulties in accepting these figures at face value as several factors may help explain this difference. Naproxen, which has a sustained antiplatelet effect for 8 h following ingestion, may actually have a cardioprotective effect and reduce the risk of MI by its aspirin-like inhibition of TXA 2 .
19 Alternatively, as a greater than standard dose of rofecoxib was used in the study, this may have increased the incidence of hypertension and therefore cardiovascular risk. In addition, the study population were not permitted to be on aspirin, anticoagulants or other antiplatelet agents and when analysed, over a third of those who had had an MI would have met FDA criteria for aspirin use for secondary cardiovascular prophylaxis.
The second large RCT, CLASS, compared the annualised rates of upper GI complications and symptomatic ulcers for patients with RA and OA on celecoxib 400 mg b.d. compared to ibuprofen 800 mg t.d.s. and diclofenac 75 mg b.d. There were no excess cardiovascular events in the celecoxib group even when those not on aspirin, which was permitted in this study, were analysed. 14 To examine this possible effect of COX-2 inhibition on ischaemic events further, several retrospective cohort studies and meta-analyses have attempted to clarify this concern. Ray et al 20 performed a retrospective cohort study of 378 776 individuals aged between 50 and 85 years on the expanded Tennessee Medicaid programme, who were either nonusers or taking rofecoxib, celecoxib or other nonaspirin NSAIDs. The main end point was defined as hospital admission for acute MI or fatal coronary heart disease (CHD). The rofecoxib group was then subdivided into those taking 25 mg or less and those taking over 25 mg. The high-dose rofecoxib group had an event rate 1.70 (95% CI 0.98-2.95) times that for nonusers and 1.78 (95% CI 0.99-3.21) times that for celecoxib users. There was no increase in risk of serious CHD events in those taking 25 mg or less of rofecoxib, celecoxib or the nonaspirin NSAIDs. Another study reviewed more than 28 000 patients in 23 phase II-V rofecoxib studies and concluded that there was an increased risk with the drug when comparing rofecoxib with naproxen (1.69 relative risk) but not comparing rofecoxib with placebo or non-naproxen NSAIDs, 21 supporting an effective antiplatelet role for naproxen. In a similar analysis for phase II-V clinical trial data for celecoxib, no differences were seen between celecoxib and placebo and celecoxib and all NSAIDs. 22 There is a definite need for large longterm comparative RCTs with hypertension and cardiovascular events as defined primary end points before we are able conclude more definitely about risk of using these drugs in our patient group.
Conclusion
From the data reviewed, we conclude that COX-2 inhibitors appear to affect BP to a similar extent as standard NSAIDs and the long-term effect of this may be an adverse effect on the incidence of cardiovascular events. Additional risks may be induced by alteration of the physiological balance between vasodilatory and vasoconstrictor prostanoids, and unopposed activity of prothrombotic COX-1-mediated thromboxane. Whether these factors translate into an actual increased risk of ischaemic events in patients with chronic arthritis is by no means clear at present. COX-2 inhibitors COX-2 inhibition and CV risk E Justice and DM Carruthers provide symptomatic relief to patients with inflammatory arthritis and concerns regarding the potential cardiovascular effects should be balanced against their proven efficacy and improved gastrointestinal profile. Before the prescription of any COX-2 inhibitor an individual risk/benefit assessment should be made and once treatment is started close monitoring of blood pressure is required along with modification of other cardiovascular and gastrointestinal risk factors.
